Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 4.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-AAK1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
AAK1 also known as adaptor-associated kinase 1 is a protein kinase with a molecular weight of 88 kDa. It plays a significant role in the regulation of clathrin-mediated endocytosis. AAK1 phosphorylates the mu2 subunit of the AP2 complex which is critical for the recruitment of clathrin to membranes. This protein is expressed in various tissues with high levels noted in the brain and spinal cord. AAK1 also participates in the modulation of neurotransmitter receptors and synaptic vesicle function.
Biological function summary
AAK1 functions as part of the AP2 clathrin adaptor complex which is essential for the internalization of cargo at the plasma membrane. Its activity is important for maintaining proper cellular uptake of nutrients receptors and signaling molecules. In neurons AAK1 regulates the cycle of synaptic vesicles impacting neurotransmission by influencing vesicle release and recycling. It has been suggested that AAK1 also contributes to the modulation of dendritic spine morphology through its kinase activity.
Pathways
AAK1 participates in endocytosis and intracellular trafficking pathways. It is directly involved in the clathrin-mediated endocytic route interacting with other proteins such as clathrin and dynamin. This association with clathrin provides a mechanism for cargo selection and membrane curvature linking AAK1 to the broader system of intracellular transport. In addition AAK1 connects to MAPK signaling through potential cross-talk mechanisms highlighting its role in cellular signaling regulation.
AAK1 has connections to neurodegeneration and cancer. In diseases like Alzheimer's abnormal function or expression of AAK1 can affect synaptic activity potentially exacerbating memory loss and cognitive decline. AAK1 also shows altered expression patterns in some cancers suggesting a role in oncogenic pathways. Its interaction with proteins like ALK and Ret may influence cell migration and proliferation reflecting AAK1's impact on disease states.
